Selumetinib - Latest Advances

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Journal: No shinkei geka. Neurological surgery

Published: December 09, 2025

Targeting Radiation-Induced Glioma-Initiating Cells in Patient-Derived Glioblastoma.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Modeling MEK inhibitor-Associated Retinopathy in vitro using human induced pluripotent stem cell-derived retinal pigment epithelial cells.

Journal: bioRxiv : the preprint server for biology

Published: November 19, 2025

Clinical benefits of selumetinib in adults with neurofibromatosis type 1 - Authors' reply.

Journal: Lancet (London, England)

Published: October 27, 2025

Development of selumetinib-loaded solid dispersion based on low molecular weight methylcellulose for the enhanced solubility, stability, dissolution, and bioavailability.

Journal: International journal of biological macromolecules

Published: October 09, 2025

Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib.

Journal: Skin therapy letter

Published: September 24, 2025

RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage-Tumor Interactions in the Glioblastoma Microenvironment.

Journal: Cancers

Published: August 28, 2025

Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: August 27, 2025

Integrative Genomic and Immune Profiling to Identify and Characterize High-Risk Subgroups in Acute Myeloid Leukemia: Development of a 20-Gene Predictive Signature and Its Clinical Implications.

Journal: Omics : a journal of integrative biology

Published: August 22, 2025

Temsirolimus targets chemoresistant uveal melanoma via mammalian target of rapamycin inhibition and enhances chemotherapy.

Journal: Anti-cancer drugs

Published: August 21, 2025

A Nonparametric Population Pharmacokinetic Model of Selumetinib in Pediatric Patients Diagnosed With Neurofibromatosis-I or Plexiform Neurofibromas.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 19, 2025

Visual Improvement in a Child With Periorbital Plexiform Neurofibroma Treated With Selumetinib: Case Report and Literature Review.

Journal: Ophthalmic plastic and reconstructive surgery

Published: August 11, 2025

Filters

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors

Targeting Radiation-Induced Glioma-Initiating Cells in Patient-Derived Glioblastoma.

Targeting Radiation-Induced Glioma-Initiating Cells in Patient-Derived Glioblastoma.

Modeling MEK inhibitor-Associated Retinopathy in vitro using human induced pluripotent stem cell-derived retinal pigment epithelial cells.

Modeling MEK inhibitor-Associated Retinopathy in vitro using human induced pluripotent stem cell-derived retinal pigment epithelial cells.

Clinical benefits of selumetinib in adults with neurofibromatosis type 1 - Authors' reply.

Clinical benefits of selumetinib in adults with neurofibromatosis type 1 - Authors' reply.

Development of selumetinib-loaded solid dispersion based on low molecular weight methylcellulose for the enhanced solubility, stability, dissolution, and bioavailability.

Development of selumetinib-loaded solid dispersion based on low molecular weight methylcellulose for the enhanced solubility, stability, dissolution, and bioavailability.

Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib.

Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib.

RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage-Tumor Interactions in the Glioblastoma Microenvironment.

RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage-Tumor Interactions in the Glioblastoma Microenvironment.

Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis.

Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis.

Integrative Genomic and Immune Profiling to Identify and Characterize High-Risk Subgroups in Acute Myeloid Leukemia: Development of a 20-Gene Predictive Signature and Its Clinical Implications.

Integrative Genomic and Immune Profiling to Identify and Characterize High-Risk Subgroups in Acute Myeloid Leukemia: Development of a 20-Gene Predictive Signature and Its Clinical Implications.

Temsirolimus targets chemoresistant uveal melanoma via mammalian target of rapamycin inhibition and enhances chemotherapy.

Temsirolimus targets chemoresistant uveal melanoma via mammalian target of rapamycin inhibition and enhances chemotherapy.

A Nonparametric Population Pharmacokinetic Model of Selumetinib in Pediatric Patients Diagnosed With Neurofibromatosis-I or Plexiform Neurofibromas.

A Nonparametric Population Pharmacokinetic Model of Selumetinib in Pediatric Patients Diagnosed With Neurofibromatosis-I or Plexiform Neurofibromas.

Visual Improvement in a Child With Periorbital Plexiform Neurofibroma Treated With Selumetinib: Case Report and Literature Review.

Visual Improvement in a Child With Periorbital Plexiform Neurofibroma Treated With Selumetinib: Case Report and Literature Review.